Johnson & Johnson Invests $1 Billion in Pennsylvania

Johnson & Johnson has announced plans to invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania, further strengthening its U.S. production footprint and advancing its pipeline of innovative medicines.

The new facility will focus on manufacturing advanced cell therapies designed to treat cancer, immune-mediated conditions, and neurological diseases. The investment underscores the company’s strategy to expand domestic manufacturing capacity while accelerating the development and delivery of transformational treatments to patients.

Chairman and Chief Executive Officer Joaquin Duato said the move reflects the company’s longstanding commitment to American healthcare innovation. “For 140 years, Johnson & Johnson has been a leading innovator in American healthcare, and we are honored to continue advancing that legacy in Pennsylvania,” Duato said. He added that combining scientific excellence with advanced manufacturing capabilities and strategic investments allows the company to deliver meaningful outcomes for patients while creating economic opportunities for local communities.

The Montgomery County facility will incorporate state-of-the-art biomanufacturing technologies and processes, aligning with the rapidly evolving field of cell and gene therapies. These treatments, which often involve modifying a patient’s own cells to fight disease, require highly specialized production environments and skilled technical expertise. By expanding its manufacturing network, Johnson & Johnson aims to ensure reliable supply as demand for advanced therapies continues to grow.

The project is expected to generate substantial economic benefits. Once fully operational, the facility will support more than 500 skilled biomanufacturing jobs. During the construction phase, the development is projected to create over 4,000 jobs, providing a significant boost to the local economy.

Pennsylvania Governor Josh Shapiro welcomed the announcement, highlighting the state’s progress in life sciences and advanced manufacturing. He noted that recent economic development initiatives, including streamlining regulations and investing strategically in high-growth sectors, have helped position Pennsylvania as a competitive destination for major life sciences investments. According to Shapiro, the state’s focus on workforce development and industry partnerships has been instrumental in attracting companies like Johnson & Johnson to expand operations within the Commonwealth.

The investment reflects broader industry trends as biopharmaceutical companies increase domestic manufacturing capabilities to enhance supply chain resilience and support innovation. For Johnson & Johnson, the new facility represents a significant step in reinforcing its leadership in next-generation therapies while deepening its roots in Pennsylvania’s growing life sciences ecosystem.